Another study from Southern Europe, in Italy, Neopearl, involved a nationwide collaboration recruiting 271 patients with HER-2 positive Stage II-III breast cancer, with a pCR rate of 55.7%. The gene discussed is ERBB2; the disease is breast carcinoma.